Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14426282 | 0.97 | GRIN2B (0.37) | GRIN2B | |
| SCHEMBL5411953 | 0.91 | APEX1 (0.44) | KDM4ELMNACYP1A2HSD17B10HTR1A | |
| SCHEMBL5416655 | 0.87 | APEX1 (0.43) | KDM4ELMNACYP1A2HSD17B10 | |
| SCHEMBL5412475 | 0.86 | MAPT (0.48) | GRIN2B | |
| SCHEMBL5414934 | 0.83 | GLA (0.53) | KDM4E | |
| SCHEMBL5419233 | 0.82 | MEN1 (0.45) | KDM4ELMNA | |
| SCHEMBL5430232 | 0.79 | HTT (0.44) | LMNADRD2 | |
| SCHEMBL5413564 | 0.72 | APEX1 (0.38) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL5425114 | 0.71 | TSPO (0.47) | KDM4E | |
| SCHEMBL5419202 | 0.70 | TSPO (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191447-A1 | Novel heterocyclic compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191447-A1 | Novel heterocyclic compound | OPRD1, GRIN3A, GRM3 | KDM4E 2970/4885LMNA 3597/4885CYP1A2 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.